tbuckley/cabot-search huggingface dataset:
A Novel Role For Histone Deacetylase 11 (HDAC11) As a Regulator Of Neutrophil Function and Differentiation In Normal and Malignant Hematopoesis
Authors: Eva Sahakian, John Powers, Jie Chen, Allison Distler, Jennifer Rock-Klotz, Susan Deng, Sheng Wei, Eduardo M. Sotomayor, Javier Pinilla-Ibarz, Pedro Horna
Journal: Blood (2013)
ANTICOAGULANTS IN THE TREATMENT OF CORONARY THROMBOSIS
Authors: P. W. C.
Journal: Annals of Internal Medicine (1949)

Editorial1 February 1949ANTICOAGULANTS IN THE TREATMENT OF CORONARY THROMBOSISP. W. C.P. W. C.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-30-2-436 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe high and apparently increasing frequency of coronary thrombosis and myocardial infarction in our aging population as well as the dramatically abrupt onset and high mortality has emphasized the need for more effective measures of treatment. The conventional measures now in use, which are largely only supportive and symptomatic, doubtless facilitate survival in many cases, but the average mortality of about 20 per cent during the first attack manifestly leaves much to be desired.For the underlying pathological changes in the coronary arteries little or nothing has been accomplished, and at present not much of a curative nature can be...1 SOLANDTBEST DYCH: Heparin and coronary thrombosis in experimental animals, Lancet, 1938, ii, 130-132. CrossrefGoogle Scholar2 PETERSGUYTHERBRAMBEL HRJRCE: Dicumarol in acute coronary thrombosis, Jr. Am. Med. Assoc., 1946, cxxx, 398-402. CrossrefGoogle Scholar3 WRIGHT IS: Experiences with dicumarol (3, 3′methylene-bis-(4 hydroxycoumarin)) in the treatment of coronary thrombosis with myocardial infarction, Am. Heart Jr., 1946, xxxii, 20-31. CrossrefGoogle Scholar4 NICHOLPAGE ESSW: Dicumarol therapy in acute coronary thrombosis; results in fifty attacks, Jr. Florida Med. Assoc., 1946, xxxii, 365-370. Google Scholar5 ASKEYNEURATH JMO: Is digitalis indicated in myocardial infarction? Jr. Am. Med. Assoc., 1945, cxxviii, 1016. CrossrefGoogle Scholar6 WRIGHTMARPLEBECK ISCDDF: Anticoagulant therapy of coronary thrombosis, Jr. Am. Med. Assoc., 1948, cxxxviii, 1074-1079. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAn evaluation of anticoagulant therapy in myocardial infarction based on prognostic categories 1 February 1949Volume 30, Issue 2Page: 436-439KeywordsAgingAnticoagulantsCoronary arteriesMortalityMyocardial infarctionThrombosis ePublished: 1 December 2008 Issue Published: 1 February 1949 PDF downloadLoading ...
Chikungunya outbreak in Montpellier, France, September to October 2014
Authors: E Delisle, C Rousseau, B Broche, I Leparc-Goffart, G L’Ambert, A Cochet, C Prat, V Foulongne, J B Ferré, O Catelinois, O Flusin, E Tchernonog, I E Moussion, A Wiegandt, A Septfons, A Mendy, M B Moyano, L Laporte, J Maurel, F Jourdain, J Reynes, M C Paty, F Golliot
Journal: Eurosurveillance (2015)

In October 2014, an outbreak of 12 autochthonous chikungunya cases, 11 confirmed and 1 probable, was detected in a district of Montpellier, a town in the south of France colonised by the vector Aedes albopictus since 2010. A case returning from Cameroon living in the affected district was identified as the primary case. The epidemiological investigations and the repeated vector control treatments performed in the area and around places frequented by cases helped to contain the outbreak. In 2014, the chikungunya and dengue surveillance system in mainland France was challenged by numerous imported cases due to the chikungunya epidemic ongoing in the Caribbean Islands. This first significant outbreak of chikungunya in Europe since the 2007 Italian epidemic, however, was due to an East Central South African (ECSA) strain, imported by a traveller returning from West Africa. Important lessons were learned from this episode, which reminds us that the threat of a chikungunya epidemic in southern Europe is real.
Method for Cytological Detection of Tumor Cells in Mouse Blood &lt;italic&gt;In Vitro&lt;/italic&gt;
Authors: Marvin M. Romsdahl, M.D., Elizabeth W. Chu, M.D., Roxane Hume, B.S., Robert R. Smith, M.D.
Journal: JNCI Journal of the National Cancer Institute (1961)

A procedure for isolation of tumor cells from whole blood of mice is described, which utilizes Dextran and the Millipore filter technique. The cytological characteristics of isolated tumor cells are preserved and there is minimal loss of cells. Leukocytes and tumor cells can easily be differentiated and screened.
Abstract IA10: microRNAs and lncRNAs in mammalian physiology and cancer
Authors: Joshua T. Mendell
Journal: Cancer Research (2016)

Abstract Gain- and loss-of-function of noncoding RNAs can potently influence cellular behavior in normal physiologic states and in diseases such as cancer. In particular, dysregulation of microRNA (miRNA) expression has been clearly shown to result in dramatic phenotypic consequences. We previously demonstrated extensive control of miRNA expression by well-characterized oncogenic and tumor suppressor networks including the MYC, KRAS, and p53 pathways. More recently, we have uncovered germline and somatic mutations in core miRNA processing components such as DROSHA and DICER in tumors. The analysis of novel mouse models with gain- and loss- of miRNA function has revealed potent, and often unexpected, consequences of dysregulated miRNA expression and activity in vivo. More recently, we have applied these same approaches to dissect novel mechanisms of long noncoding RNA (lncRNA) regulation and function in mammalian physiology and cancer. I will present our latest results related to the regulation and function of noncoding RNAs and how these findings may be exploited for the development of novel therapeutic approaches. Citation Format: Joshua T. Mendell. microRNAs and lncRNAs in mammalian physiology and cancer. [abstract]. In: Proceedings of the AACR Special Conference on Noncoding RNAs and Cancer: Mechanisms to Medicines ; 2015 Dec 4-7; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2016;76(6 Suppl):Abstract nr IA10.
Microbial Synergism in Human Infections
Authors: Philip A. Mackowiak
Journal: New England Journal of Medicine (1978)

Microbial Interactions Resulting in Facilitated Colonization of Potential HostsAlthough polymicrobial infections occur with regularity in immunosuppressed patients, the combination of Pneumocystis carinii and cytomegalovirus infections occurs much more frequently in these patients than one would expect to see by chance alone.78 , 79 Of the many hypotheses that have been proposed to explain this association, a recent proposal is particularly intriguing.79 Cytomegalovirus-like bodies have been observed within P. carinii in patients with combined pneumocystis and cytomegalovirus pneumonia, leading to speculation that in patients with dual infections the parasitized pneumocystis might act as a vector for cytomegalovirus or, alternatively that the patient . . .
Technologic Advances in Surgery for Brain Tumors: Tools of the Trade in the Modern Neurosurgical Operating Room
Authors: Christopher M. McPherson, Raymond Sawaya
Journal: Journal of the National Comprehensive Cancer Network (2005)

Surgery is an essential part of the oncologic treatment of patients with brain tumors. Surgery is necessary for histologic diagnosis, and the cytoreduction of tumor mass has been shown to improve patient survival time and quality of life. Ultimately, the goal of any oncologic neurosurgery is to achieve maximal safe resection. Over the years, many technologic adjuncts have been developed to assist the surgeon in achieving this goal. In this article, we review the technologic advances of modern neurosurgery that are helping to reach this goal.
One in three female clinician-researchers reports sexual harassment, US survey finds
Authors: Michael McCarthy
Journal: BMJ (2016)

One in three female clinician-researchers reports having been sexually harassed during her professional career, a US survey has found. Of those who experienced more severe forms of harassment, nearly half reported that the experiences had harmed their careers.1

In the study, questionnaires were sent to 1719 male and female recipients of career development awards from the US National Institutes of Health from 2006 through 2009. Questions about gender bias, gender advantages, and sexual harassment were included in the questionnaire, along …
Dementia with coexistent major depression
Authors: B S Greenwald, E Kramer-Ginsberg, D B Marin, L B Laitman, C K Hermann, R C Mohs, K L Davis
Journal: American Journal of Psychiatry (1989)

Eleven percent (N = 25) of 232 dementia patients seen in an active geropsychiatry service also met criteria for major depression. Ten patients with dementia/depression were prospectively compared with 10 non-depressed demented and 33 nondemented depressed patients on pretreatment and posttreatment ratings of depression and cognition/memory. Seventy percent (N = 7) of the dementia/depression group and 73% (N = 24) of the depression-only group responded to antidepressant therapy. Signs and symptoms of depression complicating dementia were similar to depressive phenomena in the depression-only group. Depression with dementia appeared to lower performance on cognitive tests. Following treatment, although cognitive impairment remained in the demented range, test performance improved.
Makers of John Hunter
Authors: W. S. Handley
Journal: BMJ (1939)

atque vale.I rejoice to think that Sir D'Arcy Power, in his Lives of the Fellows, will supply the defects of this brief survey of our losses, and that nearly 300 new Fellows have taken their places in the unending procession.It is a tribute to the broad-mindedness of my country- men that John Hunter, the presiding genius of this College of Surgeons of England, was not an Englishman.Nothing,
The Genetics of Transplantation<xref ref-type="fn" rid="fn1">1</xref><xref ref-type="fn" rid="fn2">2</xref>
Authors: George D. Snell, Sc.D.
Journal: JNCI Journal of the National Cancer Institute (1953)

The Genetics of Transplantation Get access George D. Snell, Sc.D. George D. Snell, Sc.D. Roscoe B. Jackson Memorial Laboratory, Bar Harbor, Maine3 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 14, Issue 3, December 1953, Pages 691–704, https://doi.org/10.1093/jnci/14.3.691 Published: 01 December 1953
Studies of adoptees from psychiatrically disturbed biological parents. III. Medical symptoms and illnesses in childhood and adolescence
Authors: R J Cadoret, L Cunningham, R Loftus, J Edwards
Journal: American Journal of Psychiatry (1976)

Analysis of data gathered from interviews with adoptive parents supports the hypothesis that female adoptees of antisocial biological backgrounds might have higher percentages of somatic symptoms. The authors compared female adoptees of antisocial parentage with male and female controls, male adoptees of antisocial parentage, and male and female adoptees whose biological parents had other psychiatric conditions. They stress the importance of this hypothesis in the diagnosis and management of childhood and adolescent "medical" and behavioral problems.
Abstract P6-07-13: New insights on HER2 amplification from the constitutional and somatic standpoints: Results from the ICGC and SIGNAL/Phare studies
Authors: A Vincent-Salomon, A Ferrari, X Pivot, G Macgrogan, L Arnould, I Treilleux, G Romieux, A-S Sertier, E Thomas, L Tonon, S Boyault, J Kielbassa, V Letexier, I Pauporte, D Birbaum, P Saintigny, D Cox, A Viari
Journal: Cancer Research (2016)

Abstract Background: HER2-positive (HER2+) breast cancers are defined by the amplification and/or overexpression of the human epidermal growth factor receptor (HER2/ERBB2) gene on chromosome region 17q12. Although anti-HER2 targeted therapies have greatly improved treatment of HER2+ breast cancer, the magnitude of benefit varies widely between patients. Deciphering the genomic and genetic heterogeneity of HER2+ breast cancer may provide a basis to better understand their natural history, opening new avenues of treatment. Methods: As part of the ICGC Breast Cancer Working Group effort, we combined whole genome sequencing and transcriptomic analyses of 64 HER2+ primary invasive carcinomas, and a genome wide association study (GWAS) of over 9.836 breast cancer patients in the prospective SIGNAL/PHARE cohort (NCT00381901 – RECF1098). Results: Using WGS data we precisely delineate the ERBB2 amplicon as a 106 kb region involving six genes and show that the amplification mechanism was consistent with breakage-fusion-bridge (BFB) cycles. Four RNA expression-based groups were identified, displaying specific genomic alterations in terms of amplification, rearrangements and mutations. On other hand, GWAS analyses failed to identify any constitutional variants associated with HER2 amplification. Discussion: By combining whole genome sequencing and expression analysis, we provide evidence showing that HER2+ tumours display considerably more molecular heterogeneity than previously reported. These results are reinforced with the lack of association between any genetic variants and HER2 amplification from GWAS analyses. Taken as a whole, these results suggest that HER2+ breast cancers do not represent per se a homogeneous subtype, but are distributed along the whole breast cancer spectrum, from ER-positive luminal to ER-negative basal phenotype. Genome alterations present in HER2+ tumors are in accordance with these phenotypes, and it is likely that the HER2 amplification is a secondary event in the course of tumorigenesis, not favored by any particular constitutional or somatic genetic variants. Citation Format: Vincent-Salomon A, Ferrari A, Pivot X, Macgrogan G, Arnould L, Treilleux I, Romieux G, Sertier A-S, Thomas E, Tonon L, Boyault S, Kielbassa J, Letexier V, Pauporte I, Birbaum D, Saintigny P, Cox D, Viari A. New insights on HER2 amplification from the constitutional and somatic standpoints: Results from the ICGC and SIGNAL/Phare studies. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-07-13.
Counseling and DNA Testing for Individuals Perceived to Be Genetically Predisposed to Melanoma: A Consensus Statement of the Melanoma Genetics Consortium
Authors: Richard F. Kefford, Julia A. Newton Bishop, Wilma Bergman, Margaret A. Tucker
Journal: Journal of Clinical Oncology (1999)

Article Tools Melanoma Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1999.17.10.3245 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 10506626 Counseling and DNA Testing for Individuals Perceived to Be Genetically Predisposed to Melanoma: A Consensus Statement of the Melanoma Genetics Consortium Richard F. KeffordxRichard F. KeffordSearch for articles by this author , Julia A. Newton BishopxJulia A. Newton BishopSearch for articles by this author , Wilma BergmanxWilma BergmanSearch for articles by this author , Margaret A. TuckerxMargaret A. TuckerSearch for articles by this author , Show More From the Westmead Institute for Cancer Research, University of Sydney, Westmead Hospital, New South Wales, Australia; Imperial Cancer Research Fund (ICRF) Cancer Medicine Research Unit and ICRF Genetic Epidemiology, St James's University Hospital, Leeds, United Kingdom; Leiden University Medical Centre, Leiden, the Netherlands; and National Cancer Institute, Rockville, MD. https://doi.org/10.1200/JCO.1999.17.10.3245 First Page Full Text PDF Figures and Tables © 1999 by American Society of Clinical Oncology
Association Between Pretransplant Interferon-α and Outcome After Unrelated Donor Marrow Transplantation for Chronic Myelogenous Leukemia in Chronic Phase
Authors: A. James Morton, Ted Gooley, John A. Hansen, Frederick R. Appelbaum, Barbara Bruemmer, Jean W. Bjerke, Reg Clift, Paul J. Martin, Effie W. Petersdorf, Jean E. Sanders, Rainer Storb, Keith M. Sullivan, Ann Woolfrey, Claudio Anasetti
Journal: Blood (1998)
Taxonomer: an interactive metagenomics analysis portal for universal pathogen detection and host mRNA expression profiling
Authors: Steven Flygare, Keith Simmon, Chase Miller, Yi Qiao, Brett Kennedy, Tonya Di Sera, Erin H. Graf, Keith D. Tardif, Aurélie Kapusta, Shawn Rynearson, Chris Stockmann, Krista Queen, Suxiang Tong, Karl V. Voelkerding, Anne Blaschke, Carrie L. Byington, Seema Jain, Andrew Pavia, Krow Ampofo, Karen Eilbeck, Gabor Marth, Mark Yandell, Robert Schlaberg
Journal: Genome biology (2016)

High-throughput sequencing enables unbiased profiling of microbial communities, universal pathogen detection, and host response to infectious diseases. However, computation times and algorithmic inaccuracies have hindered adoption.We present Taxonomer, an ultrafast, web-tool for comprehensive metagenomics data analysis and interactive results visualization. Taxonomer is unique in providing integrated nucleotide and protein-based classification and simultaneous host messenger RNA (mRNA) transcript profiling. Using real-world case-studies, we show that Taxonomer detects previously unrecognized infections and reveals antiviral host mRNA expression profiles. To facilitate data-sharing across geographic distances in outbreak settings, Taxonomer is publicly available through a web-based user interface.Taxonomer enables rapid, accurate, and interactive analyses of metagenomics data on personal computers and mobile devices.
Effects of smoking on free recall and organization
Authors: J P Houston, N G Schneider, M E Jarvik
Journal: American Journal of Psychiatry (1978)

Habitual smokers smoked either nicotine-free cigarettes or cigarettes containing a known amount of nicotine and then engaged in a free-recall task. Nicotine subjects recalled significantly fewer words on a 75-item list during three successive trials of immediate recall than did nicotine-free subjects. Contrary to expectations, the superiority of the nonnicotine group persisted over two days. The two groups displayed comparable organizational activity (indexed by category clustering).
BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients
Authors: CM Verfaillie, R Bhatia, W Miller, F Mortari, V Roy, S Burger, J McCullough, K Stieglbauer, G Dewald, S Heimfeld, JS Miller, PB McGlave
Journal: Blood (1996)
Abstract P5-08-22: DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer
Authors: B Györffy, G Munkacsy, FJ Esteva, TP Miquel, O Menyhart
Journal: Cancer Research (2016)

Abstract Background. The majority of patients develop resistance against suppression of HER2-mediated signaling by trastuzumab in HER2 positive breast cancer (BC). HER2 overexpression activates multiple signaling pathways, including the mitogen-activated protein kinase (MAPK) cascade. MAPK phosphatases (MKPs) are essential regulators of MAPKs and participate in many facets of cellular regulation, including proliferation and apoptosis. We aimed to identify whether differential MKPs are associated with resistance to targeted therapy in patients previously treated with trastuzumab. Methods. Using Affymetrix HGU133plus2 gene chip data of 88 HER2-positive, trastuzumab treated BC patients, candidate MKPs were identified by Receiver Operator Characteristics analysis performed in R. Genes were ranked using their achieved area under the curve (AUC) values and were further constricted to those markers significantly associated to worse survival. Functional significance of the two strongest predictive biomarkers was evaluated in vitro experiments after gene silencing in the HER2 overexpressing, trastuzumab resistant breast cancer cell lines SKBR-3-TR and JIMT-1. Results. Out of 10 investigated MKPs, the strongest predictive genes were DUSP4/MKP2 (AUC=0.75, p=0.0096) and DUSP6/MKP3 (AUC=0.77, p=5.29E-05). Furthermore, higher expression for these correlated to worse survival in 221 HER2 positive BC patients (DUSP4: HR=1.6, p=0.04 and DUSP6: HR=1.8, p=0.0053). Silencing of DUSP4 had significant sensitization effects - viability of DUSP4 siRNA transfected, trastuzumab treated cells decreased significantly compared to scramble-siRNA transfected, trastuzumab treated controls (SKBR-3-TR: p=0.016; JIMT-1: p=0.016). In contrast, simultaneous treatment with DUSP6 siRNA and trastuzumab did not alter cell proliferation. Conclusions. Our findings suggest that DUSP4 is involved in the development of trastuzumab resistance in HER2 positive BC. Citation Format: Györffy B, Munkacsy G, Esteva FJ, Miquel TP, Menyhart O. DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-08-22.
Peripapillary Diffuse Chorioretinal Atrophy in Children as a Sign of Eventual Pathologic Myopia in Adults
Authors: Tae Yokoi, Jost B. Jonas, Noriaki Shimada, Natsuko Nagaoka, Muka Moriyama, Takeshi Yoshida, Kyoko Ohno-Matsui
Journal: Ophthalmology (2016)
Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant <i>KRAS</i> Lung Cancer
Authors: Ke-Jing Tang, Jerfiz D. Constanzo, Niranjan Venkateswaran, Margherita Melegari, Mariya Ilcheva, Julio C. Morales, Ferdinandos Skoulidis, John V. Heymach, David A. Boothman, Pier Paolo Scaglioni
Journal: Clinical Cancer Research (2016)

Abstract Purpose: Non–small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide due to the limited availability of effective therapeutic options. For instance, there are no effective strategies for NSCLCs that harbor mutant KRAS, the most commonly mutated oncogene in NSCLC. Thus, our purpose was to make progress toward the generation of a novel therapeutic strategy for NSCLC. Experimental Design: We characterized the effects of suppressing focal adhesion kinase (FAK) by RNA interference (RNAi), CRISPR/CAS9 gene editing or pharmacologic approaches in NSCLC cells and in tumor xenografts. In addition, we tested the effects of suppressing FAK in association with ionizing radiation (IR), a standard-of-care treatment modality. Results: FAK is a critical requirement of mutant KRAS NSCLC cells. With functional experiments, we also found that, in mutant KRAS NSCLC cells, FAK inhibition resulted in persistent DNA damage and susceptibility to exposure to IR. Accordingly, administration of IR to FAK-null tumor xenografts causes a profound antitumor effect in vivo. Conclusions: FAK is a novel regulator of DNA damage repair in mutant KRAS NSCLC and its pharmacologic inhibition leads to radiosensitizing effects that could be beneficial in cancer therapy. Our results provide a framework for the rationale clinical testing of FAK inhibitors in NSCLC patients. Clin Cancer Res; 22(23); 5851–63. ©2016 AACR.